Gadeta B.V., is a Dutch start-up company focused on the discovery and development of novel cancer immunotherapies based on gamma delta T cell receptors.
Gadeta B.V., is a Dutch start-up company focused on the discovery and development of novel cancer immunotherapies based on gamma delta (??) T cell receptors.
Gadeta is established on the ground-breaking discoveries of Prof. Dr. JÈrgen Kuball at University Medical Centre Utrecht (UMCU) in The Netherlands, regarding the role of ?? T cell receptors in the broad recognition of the metabolic differences in Cancer.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/gadeta” connections=”true” suffix=””]
Gadetas technology platform utilizes combinatorial T Cell receptor exchange (CTE) to create optimized gamma delta (??) T-cell receptors (TCRs) with an enhanced anti-cancer reactivity. Gadetas new cell-based anti-cancer product called T Cells are Engineered To Express A Defined Gamma Delta TCR (TEGs) has strong therapeutic potential for combating and eradicating both hematological and solid tumors.
In Mar 2016, Gadeta raised EUR 7 Mn Series A financing round led by Baxalta Ventures, Medicxi Ventures and Utrecht Holdings.